TAKEDA PHARMACEUTICAL CO LTD current report, Q3 FY2019

Full document

Takeda Pharmaceutical Co Ltd - Q1 FY2019 Financial Summary

Business Context and Reporting Period

This Form 6-K filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2019 (Q1 FY2019). The results are prepared under International Financial Reporting Standards (IFRS). The period marks the first full quarter of consolidation following the acquisition of Shire plc, which closed on January 8, 2019. The filing includes a revision to the full-year FY2019 forecast.

Key Financial Metrics

Metric Q1 FY2019 (JPY) Q1 FY2018 (JPY) Change (%)
Revenue 849,121 Million 449,834 Million +88.8%
Operating Profit 9,866 Million 98,870 Million -90.0%
Profit Before Tax (25,186) Million 93,863 Million -126.8%
Net Profit (Loss) (20,636) Million 78,080 Million -126.4%
Core Operating Profit 283,000 Million 116,800 Million +142.3%
Underlying Core EPS 123.56 JPY n/a -
Total Assets 13,550,424 Million 13,900,023 Million (Mar 31) -2.5%
Cash & Equivalents 593,745 Million 702,093 Million (Mar 31) -15.4%
Operating Cash Flow 120,789 Million 40,471 Million +198.5%

Material Changes vs. Prior Period

  • Revenue Surge: Reported revenue nearly doubled (+88.8%) primarily due to the inclusion of three months of Shire product sales (approx. 392.2 billion JPY). Underlying revenue growth was -0.8% on a constant currency basis, reflecting generic erosion in legacy products offset by growth in key brands like ENTYVIO and VYVANSE.
  • Profitability Decline: Reported operating profit collapsed by 90.0% to 9.9 billion JPY. This was driven by significant non-cash charges related to the Shire acquisition, including 109.1 billion JPY in amortization of intangible assets and an 84.5 billion JPY inventory fair value step-up unwind.
  • Net Loss: The company reported a net loss of 20.6 billion JPY compared to a net profit of 78.1 billion JPY in the prior year, largely due to the aforementioned acquisition-related accounting impacts and increased interest expenses from Shire financing.
  • Core Performance: Excluding acquisition-related costs and non-cash items, Core Operating Profit increased 142.3% to 283.0 billion JPY, with an underlying margin of 32.4%.
  • Balance Sheet: Total equity decreased by 289.1 billion JPY from the prior fiscal year-end, primarily due to dividend payments and foreign exchange translation adjustments. Bonds and loans decreased slightly due to FX impacts and the redemption of syndicated loans, partially offset by the issuance of 500 billion JPY in hybrid bonds.

Guidance, Outlook, and Risks

  • Revised FY2019 Forecast: Management revised the full-year forecast upward for profitability metrics.
    • Revenue: Unchanged at 3,300 billion JPY (+57.4% vs FY2018).
    • Operating Profit: Revised to a loss of (166.0) billion JPY (improved by 27.0 billion JPY from previous guidance).
    • Core Operating Profit: Revised to 910.0 billion JPY (+98.1% vs FY2018).
    • EPS: Revised to a loss of (236.05) JPY.
  • Underlying Guidance: Underlying revenue growth is now projected as "Flat to slightly increasing" (previously "Flat to slightly declining"). Underlying Core EPS guidance is raised to 360-380 JPY (previously 350-370 JPY).
  • Key Drivers for Revision: The upward revision reflects better-than-expected performance from VELCADE (multiple myeloma) and the assumption that no additional U.S. competitor will launch within FY2019. This upside is expected to be offset by the divestitures of XIIDRA (completed July 2019) and TACHOSIL.
  • Risks and Contingencies:
    • Integration Costs: Significant restructuring and integration expenses related to the Shire acquisition continue to impact reported earnings.
    • Divestitures: The company is proceeding with the divestiture of XIIDRA and TACHOSIL, which will impact future revenue streams.
    • Accounting Changes: Adoption of IFRS 16 (Leases) resulted in the recognition of significant lease liabilities and right-of-use assets, altering the balance sheet structure.
    • FX Volatility: Fluctuations in foreign exchange rates, particularly the Yen, significantly impact reported financial position and comprehensive income.

Investor Verification Checklist

  • Shire Integration Progress: Verify the realization of cost synergies and the timeline for integration expense reduction to assess the path to reported profitability.
  • Core vs. Reported Divergence: Analyze the reconciliation between reported losses and strong Core Operating Profit to understand the sustainability of earnings once non-recurring acquisition costs amortize.
  • Divestiture Impact: Confirm the final terms and timing of the XIIDRA and TACHOSIL divestitures to accurately model future revenue.
  • VELCADE Competition: Monitor the U.S. market for potential new entrants in the multiple myeloma space that could invalidate the revised forecast assumptions.
  • Debt Servicing: Review the interest coverage ratio given the high level of debt assumed from Shire and the increased interest expense (up 211.4% YoY).